Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/2206
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | CORREA FILHO, Joao Maria | - |
dc.contributor.author | BALTIERI, Danilo Antonio | - |
dc.date.accessioned | 2013-09-23T16:44:49Z | - |
dc.date.available | 2013-09-23T16:44:49Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | ADDICTIVE BEHAVIORS, v.38, n.4, p.2044-2051, 2013 | - |
dc.identifier.issn | 0306-4603 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/2206 | - |
dc.description.abstract | Ondansetron has emerged as a promising medication for the treatment of alcohol dependence, mainly among early-onset alcoholics. This research primarily aimed to evaluate the efficacy and safety of ondansetron at a 16 mg/day dosage to treat alcohol-dependent outpatients. A double-blind, placebo-controlled, 12-week study was carried out at the University of Sao Paulo, Brazil. The total sample comprised 102 men, 18-60 years of age, with an International Classification of Diseases (ICD-10) diagnosis of alcohol dependence. Half of our sample discontinued the treatment and the main outcome measures (proportion of abstinent days and proportion of heavy drinking days) were analyzed using the treatment adherents as well as with an imputed sample. The main factors associated with treatment retention were older age and smoking status. Although there were no significant differences between the main outcome measures of both medication groups in the adherents, ondansetron demonstrated a slight but significant superiority over the placebo regarding the proportion of heavy drinking days in the imputed sample (7.8% versus 11.7%, respectively). It appears that the optimal dosage to treat alcoholism has yet to be determined. Further, ondansetron may only be useful in treating some types of alcoholics. Ondansetron was well tolerated and no serious adverse events were registered. | - |
dc.description.sponsorship | FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - The State of Sao Paulo Research Foundation) | - |
dc.description.sponsorship | FAPESP (The State of Sao Paulo Research Foundation) | - |
dc.language.iso | eng | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.relation.ispartof | Addictive Behaviors | - |
dc.rights | restrictedAccess | - |
dc.subject | Ondansetron | - |
dc.subject | Alcohol dependence | - |
dc.subject | Pharmacotherapy | - |
dc.subject | Clinical trial | - |
dc.subject.other | 5-ht3 receptor antagonist | - |
dc.subject.other | randomized controlled-trial | - |
dc.subject.other | serotonin transporter gene | - |
dc.subject.other | placebo-controlled trial | - |
dc.subject.other | double-blind | - |
dc.subject.other | pharmacotherapy trials | - |
dc.subject.other | parkinsons-disease | - |
dc.subject.other | promoter region | - |
dc.subject.other | rating-scale | - |
dc.subject.other | dependence | - |
dc.title | A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil | - |
dc.type | article | - |
dc.rights.holder | Copyright PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.identifier.doi | 10.1016/j.addbeh.2012.12.018 | - |
dc.identifier.pmid | 23396176 | - |
dc.subject.wos | Psychology, Clinical | - |
dc.subject.wos | Substance Abuse | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | BALTIERI, Danilo Antonio:Univ Sao Paulo, Dept Psychiat, BR-05508 Sao Paulo, Brazil; ABC Med Sch, BR-01228200 Sao Paulo, Brazil | - |
hcfmusp.description.beginpage | 2044 | - |
hcfmusp.description.endpage | 2051 | - |
hcfmusp.description.issue | 4 | - |
hcfmusp.description.volume | 38 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000316529800026 | - |
hcfmusp.origem.id | 2-s2.0-84873534441 | - |
hcfmusp.publisher.city | OXFORD | - |
hcfmusp.publisher.country | ENGLAND | - |
hcfmusp.relation.reference | Akhondzadeh S, 2009, SCHIZOPHR RES, V107, P206, DOI 10.1016/j.schres.2008.08.004 | - |
hcfmusp.relation.reference | Amorim Patricia, 2000, Revista Brasileira de Psiquiatria, V22, P106 | - |
hcfmusp.relation.reference | Annis HM, 1996, SUBST USE MISUSE, V31, P1525, DOI 10.3109/10826089609063990 | - |
hcfmusp.relation.reference | ANTON RF, 1995, ALCOHOL CLIN EXP RES, V19, P92, DOI 10.1111/j.1530-0277.1995.tb01475.x | - |
hcfmusp.relation.reference | Baltieri DA, 2012, EUR ADDICT RES, V18, P201, DOI 10.1159/000336530 | - |
hcfmusp.relation.reference | Baltieri DA, 2008, ADDICTION, V103, P2035, DOI 10.1111/j.1360-0443.2008.02355.x | - |
hcfmusp.relation.reference | Baltieri DA, 2009, DRUG ALCOHOL DEPEN, V105, P33, DOI 10.1016/j.drugalcdep.2009.05.025 | - |
hcfmusp.relation.reference | Bennett AC, 2010, ANN PHARMACOTHER, V44, P1301, DOI 10.1345/aph.1P008 | - |
hcfmusp.relation.reference | BOHN MJ, 1995, J STUD ALCOHOL, V56, P423 | - |
hcfmusp.relation.reference | Castro Luis Andre, 2004, Revista Brasileira de Psiquiatria, V26, pS43 | - |
hcfmusp.relation.reference | Chu LF, 2009, PHARMACOGENET GENOM, V19, P193, DOI 10.1097/FPC.0b013e328322e73d | - |
hcfmusp.relation.reference | CROPP CD, 1995, ANN PHARMACOTHER, V29, P1041 | - |
hcfmusp.relation.reference | de Oliveira JRM, 1998, AM J MED GENET, V81, P225, DOI 10.1002/(SICI)1096-8628(19980508)81:3<225::AID-AJMG4>3.0.CO;2-V | - |
hcfmusp.relation.reference | DYR W, 1995, ALCOHOL, V12, P387, DOI 10.1016/0741-8329(95)00023-K | - |
hcfmusp.relation.reference | Ellingstad TP, 1999, DRUG ALCOHOL DEPEN, V54, P259, DOI 10.1016/S0376-8716(98)00180-X | - |
hcfmusp.relation.reference | Fabi A, 2008, SUPPORT CARE CANCER, V16, P1375, DOI 10.1007/s00520-008-0438-9 | - |
hcfmusp.relation.reference | Faris PL, 2006, J AFFECT DISORDERS, V92, P79, DOI 10.1016/j.jad.2005.12.047 | - |
hcfmusp.relation.reference | Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146 | - |
hcfmusp.relation.reference | Friedberg G, 1998, CLIN NEUROPHARMACOL, V21, P280 | - |
hcfmusp.relation.reference | Garbutt JC, 2010, ALCOHOL CLIN EXP RES, V34, P1849, DOI 10.1111/j.1530-0277.2010.01273.x | - |
hcfmusp.relation.reference | Gilks W., 1996, MARKOV CHAIN MONTE C | - |
hcfmusp.relation.reference | Graff FS, 2009, AM J ADDICTION, V18, P277, DOI 10.1080/10550490902925540 | - |
hcfmusp.relation.reference | Gronbaek M, 2004, BIOL RES, V37, P195 | - |
hcfmusp.relation.reference | HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56 | - |
hcfmusp.relation.reference | Harmer CJ, 2006, PSYCHOPHARMACOLOGY, V186, P18, DOI 10.1007/s00213-006-0337-z | - |
hcfmusp.relation.reference | Hedeker D, 1997, PSYCHOL METHODS, V2, P64, DOI 10.1037/1082-989X.2.1.64 | - |
hcfmusp.relation.reference | Horton NJ, 2001, AM STAT, V55, P244, DOI 10.1198/000313001317098266 | - |
hcfmusp.relation.reference | Johnson BA, 2007, JAMA-J AM MED ASSOC, V298, P1641, DOI 10.1001/jama.298.14.1641 | - |
hcfmusp.relation.reference | Johnson BA, 2002, PSYCHOPHARMACOLOGY, V160, P408, DOI 10.1007/s00213-002-1002-9 | - |
hcfmusp.relation.reference | Johnson BA, 2000, JAMA-J AM MED ASSOC, V284, P963, DOI 10.1001/jama.284.8.963 | - |
hcfmusp.relation.reference | Johnson BA, 2011, AM J PSYCHIAT, V168, P265, DOI 10.1176/appi.ajp.2010.10050755 | - |
hcfmusp.relation.reference | Joseph A. M., 2004, J STUD ALCOHOL, V65, P1 | - |
hcfmusp.relation.reference | Kenna GA, 2009, ALCOHOL CLIN EXP RES, V33, P315, DOI 10.1111/j.1530-0277.2008.00835.x | - |
hcfmusp.relation.reference | Kerr WC, 2000, ADDICTION, V95, P339, DOI 10.1046/j.1360-0443.2000.9533394.x | - |
hcfmusp.relation.reference | Kranzler HR, 1996, ALCOHOL CLIN EXP RES, V20, P16, DOI 10.1111/j.1530-0277.1996.tb01036.x | - |
hcfmusp.relation.reference | Kranzler HR, 2003, ALCOHOL CLIN EXP RES, V27, P1150, DOI 10.1097/01.ALC.0000075547.77464.76 | - |
hcfmusp.relation.reference | Lachenmeier DW, 2008, REGUL TOXICOL PHARM, V50, P313, DOI 10.1016/j.yrtph.2007.12.008 | - |
hcfmusp.relation.reference | LINGJAERDE O, 1987, ACTA PSYCHIAT SCAN S, V334, pS1 | - |
hcfmusp.relation.reference | Mann K, 2010, EUR ARCH PSY CLIN N, V260, pS116, DOI 10.1007/s00406-010-0153-7 | - |
hcfmusp.relation.reference | McBride WJ, 2004, ALCOHOL CLIN EXP RES, V28, P257, DOI 10.1097/01.ALC.0000113419.99915.DA | - |
hcfmusp.relation.reference | McNulty Robert, 2007, J Natl Compr Canc Netw, V5, P35 | - |
hcfmusp.relation.reference | Meira-Lima I, 2005, J MOL NEUROSCI, V27, P219, DOI 10.1385/JMN:27:02:219 | - |
hcfmusp.relation.reference | Myrick H, 2008, ARCH GEN PSYCHIAT, V65, P466, DOI 10.1001/archpsyc.65.4.466 | - |
hcfmusp.relation.reference | Oslin DW, 2002, AM J GERIAT PSYCHIAT, V10, P740, DOI 10.1176/appi.ajgp.10.6.740 | - |
hcfmusp.relation.reference | Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100 | - |
hcfmusp.relation.reference | Piche T, 2005, GUT, V54, P1169, DOI 10.1136/gut.2004.055251 | - |
hcfmusp.relation.reference | RAISTRICK D, 1983, BRIT J ADDICT, V78, P89 | - |
hcfmusp.relation.reference | Rosner S, 2010, COCHRANE DB SYST REV, V8 | - |
hcfmusp.relation.reference | Salvucci AA, 2011, PREHOSP EMERG CARE, V15, P34, DOI 10.3109/10903127.2010.519822 | - |
hcfmusp.relation.reference | Schmidt LG, 2007, ALCOHOL ALCOHOLISM, V42, P241, DOI 10.1093/alcalc/agm027 | - |
hcfmusp.relation.reference | SELL LA, 1995, BRIT J PSYCHIAT, V166, P511, DOI 10.1192/bjp.166.4.511 | - |
hcfmusp.relation.reference | SELLERS EM, 1994, ALCOHOL CLIN EXP RES, V18, P879, DOI 10.1111/j.1530-0277.1994.tb00054.x | - |
hcfmusp.relation.reference | Sirota P, 2000, AM J PSYCHIAT, V157, P287, DOI 10.1176/appi.ajp.157.2.287 | - |
hcfmusp.relation.reference | SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3 | - |
hcfmusp.relation.reference | Soltani F, 2010, HUM PSYCHOPHARM CLIN, V25, P509, DOI 10.1002/hup.1145 | - |
hcfmusp.relation.reference | SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353 | - |
hcfmusp.relation.reference | Swift RM, 1996, BIOL PSYCHIAT, V40, P514, DOI 10.1016/0006-3223(95)00432-7 | - |
hcfmusp.relation.reference | World Health Organisation, 1992, CLASS MENT BEH DIS C | - |
hcfmusp.relation.reference | Ye JH, 2001, CNS DRUG REV, V7, P199 | - |
hcfmusp.relation.reference | ZOLDAN J, 1995, NEUROLOGY, V45, P1305 | - |
dc.description.index | MEDLINE | - |
hcfmusp.remissive.sponsorship | FAPESP | - |
hcfmusp.citation.scopus | 13 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/Outros Artigos e Materiais de Revistas Científicas - ODS/03 Artigos e Materiais de Revistas Científicas - ODS/06 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_CORREA FILHO_A_pilot_study_of_full_dose_ondansetron_to_2013.PDF Restricted Access | publishedVersion (English) | 420.17 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.